TPST Valuation
Tempest Therapeutics Inc
$
6.880
- Overview
- Forecast
- Valuation
TPST Relative Valuation
TPST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TPST is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.26
P/B
Median3y
-2.02
Median5y
-1.26
-130.30
FCF Yield
Median3y
-135.54
Median5y
-118.62
Competitors Valuation Multiple
The average P/S ratio for TPST's competitors is 23.41, providing a benchmark for relative valuation. Tempest Therapeutics Inc Corp (TPST) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
MITK
Mitek Systems Inc
8.255
USD
+1.91%
MTLS
Materialise NV
5.315
USD
+2.41%
EQV
EQV Ventures Acquisition Corp
10.230
USD
+0.29%
MREO
Mereo BioPharma Group PLC
2.670
USD
+2.69%
ANNX
Annexon Inc
1.930
USD
+4.04%
MUX
McEwen Mining Inc
7.340
USD
-2.39%
SMC
Summit Midstream Corp
27.070
USD
-0.66%
PNNT
Pennantpark Investment Corp
6.540
USD
+2.03%
KROS
Keros Therapeutics Inc
14.770
USD
+1.37%
TCBX
Third Coast Bancshares Inc
30.460
USD
+0.49%
FAQ
Is Tempest Therapeutics Inc (TPST) currently overvalued or undervalued?
Tempest Therapeutics Inc (TPST) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Tempest Therapeutics Inc (TPST) is between to according to relative valuation methord.
What is Tempest Therapeutics Inc (TPST) fair value?
How does TPST's valuation metrics compare to the industry average?
What is the current P/B ratio for Tempest Therapeutics Inc (TPST) as of May 02 2025?
What is the current FCF Yield for Tempest Therapeutics Inc (TPST) as of May 02 2025?
What is the current Forward P/E ratio for Tempest Therapeutics Inc (TPST) as of May 02 2025?